<div align="center">

<img src="../../Assets/Brand/CertiAura_Brand_Master.png" alt="CertiAura - Evidence. Clarity. Confidence." width="700">

</div>

---

# CATALOGUE COVERAGE & CLOSURE AUDIT

**Build:** 0029  
**Audit date:** 2026-07-16  
**Source scope:** `Peptides.pdf`, pages 1-5  
**Baseline:** Build 0020 master intake  
**Reviewed builds:** 0021 through 0028B

## Executive result

| Measure | Result |
|---|---:|
| Baseline SKU rows | 196 |
| Mapped SKU rows | 193 |
| Unmapped SKU rows | 3 |
| **SKU coverage** | **98.47%** |
| Baseline preliminary families | 104 |
| Mapped preliminary families | 102 |
| Unmapped preliminary families | 2 |
| **Family coverage** | **98.08%** |
| Final PKS product assets | 88 |
| Final MPS product assets | 12 |
| Final product assets | 100 |
| Product Passport assets | 12 |
| Platinum-certified catalogue assets | 0 |

## Coverage gaps

### 1. Elamipretide / SS-31

Unmapped catalogue rows:

- `2S10` - 10 mg x 10 vials - USD 85
- `2S50` - 50 mg x 10 vials - USD 360

This is a complete product-family omission from the final asset sequence.

**Required correction:** create the Elamipretide / SS-31 PKS asset and supporting evidence, safety, biology, monitoring, claims and regulatory objects.

### 2. Generic GLP-1 supplier listing

Unmapped catalogue row:

- `GP` - `GLP-1, 5mg/vial` - 5 mg x 10 vials - USD 103

The listing does not specify:

- GLP-1(7-36) amide versus GLP-1(7-37);
- native versus modified sequence;
- salt or counter-ion;
- formulation or route.

**Required correction:** identity resolution before permanent molecule-level UAI allocation. A quarantine or supplier-family object is acceptable if the identity cannot be closed.

## Deliberate consolidations

Two reductions from the original 104 preliminary families are controlled and intentional:

1. full-length thymosin beta-4 and TB-500 fragment catalogue families are retained within `CERT-PKS-000008` as an identity-controlled family;
2. the two preliminary bacteriostatic-water families are consolidated into `CERT-MPS-000007`, while `WA10`, `BA10`, `BA05` and `BA03` remain individually traceable.

Therefore:

- 104 preliminary families;
- minus 2 deliberate consolidations;
- minus 2 unmapped families;
- equals 100 final product-family assets.

## Supplemental catalogue detail

Build 0028B retains an additional detailed Lemon Bottle record, `LB10`, that was not one of the original 196 Build 0020 intake rows.

This supplemental record:

- is not counted in the 196-row coverage denominator;
- preserves the USD 85 detailed listing;
- retains the 42.5 mg/mL unexplained composition balance;
- does not overwrite the original USD 103 summary listing.

## Price control

No price mismatch was found in source rows that had a directly comparable final build-level SKU price record.

Existing baseline asset prices remain source-controlled through the original Build 0020 register and their later asset records.

## UAI state after audit

- PKS: `CERT-PKS-000001`-`CERT-PKS-000088`
- MPS: `CERT-MPS-000001`-`CERT-MPS-000012`
- PPS: `CERT-PPS-000001`-`CERT-PPS-000012`
- EKS: `CERT-EKS-000001`-`CERT-EKS-000228`
- SKS: `CERT-SKS-000001`-`CERT-SKS-000105`
- BKS: `CERT-BKS-000001`-`CERT-BKS-000178`
- CKS: `CERT-CKS-000001`-`CERT-CKS-000057`
- MKS: `CERT-MKS-000001`-`CERT-MKS-000172`
- GKS: `CERT-GKS-000001`-`CERT-GKS-000092`

## Required next build

**Build 0030A - Catalogue Coverage Correction: Elamipretide / SS-31 and Generic GLP-1 Identity Resolution**

Recommended allocation:

- `CERT-PKS-000089` - Elamipretide / SS-31
- the generic GLP-1 listing must remain unallocated or quarantined until exact identity is defensible.

No other page 1-5 coverage gap was found.
